Page 54 - IACC Newsletter June 2013 Issue 11

Basic HTML Version

Globally, the hospitality chain runs hotels and resorts under the Hyatt, Park Hyatt, Andaz,Grand Hyatt, Hyatt Regency,
Hyatt Place and Hyatt House brands. In India it has properties operating under four brands, Park Hyatt, Grand Hyatt,
Hyatt Regency, and Hyatt Place.
"We currently have 17 operational hotels in India with more than 4,900 keys. Our planned openings this year will make
this 20 hotels with over than 5,300 keys," he said. The firm will open Hyatt Regency Ludhiana by the end of this year.
"Other scheduled openings in this period are Hyatt Raipur and Hyatt Place Pune Hinjewadi," Rathore added. The
company, which last week had opened a new property at Gurgaon under the Hyatt Regency brand, has plans to open
more properties under the brand in the country.
"Apart from our six operational Hyatt Regency hotels, we are committed to another 15 under development in India,"
Rathore said without sharing a timeline.
Overall, it has over 50 ongoing projects in India across the seven different brands which would come up in due course of
time in future.
When asked about the locations for future expansion in India, he said: "Hyatt's development vision is to open hotels
where our customers are travelling for business and for leisure. We have identified opportunities in specific markets
which, apart from the metros, tier I cities, also include high growth tier II and III cities and upcoming resort/leisure
destinations."
On the investment front for the expansion, Rathore did not share a specific number saying, "We are primarily a hotel
management company and all our hotels under development in India will be operated by us under management
contracts with diverse owning companies."
Mumbai based Sun Pharma gets USFDA nod for testosterone cypionate injection.
Drug firm Sun Pharmaceutical Industries today said it has received final approval from the US health regulator for its
generic testosterone cypionate injection indicated for treatment of testosterone hormone deficiency.
"The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new
drug application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP," Sun
Pharma said in a statement.
The approval is for the product in the strengths of 100 mg/ml and 200mg/ml, it added. The company's generic
testosterone cypionate injection is therapeutically equivalent to Pfizer Inc.'s Depo Testosterone injection, Sun Pharma
said.
"As per April-2013 IMS MAT data, the product had annual revenues of approximately USD 130 million in the US," it
added. The injection is indicated for replacement therapy in males in conditions associated with symptoms of deficiency
or absence of endogenous testosterone, Sun Pharma said.
Andhra Pradesh to partner with MIT to improve education
Andhra Pradesh is set to sign a memorandum of understanding (MOU) with the Massachusetts Institute of Technology
to tap its vast resources to help give the state's educational system a facelift, the state's Information Technology and
Communications Minister Ponnala Lakshmaiah said here today. He said the details were being worked out and the MOU
would be signed soon.